Gain Therapeutics 관리

관리 기준 확인 1/4

Gain Therapeutics CEO는 Gene Mack, Apr2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 23.33K 가치에 해당하는 회사 주식의 0.056% 직접 소유합니다. 23.33K. 경영진과 이사회의 평균 재임 기간은 각각 0.8 년과 3.8 년입니다.

주요 정보

Gene Mack

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.06%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 29

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 12

Gain Therapeutics appoints CEO

Sep 20

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Oct 27

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Aug 19

Gain Therapeutics EPS misses by $0.29

May 10

CEO

Gene Mack

less than a year

테뉴어

Mr. Gene Mack, M.B.A. is Chief Financial Officer of Gain Therapeutics, Inc. from April 8, 2024 & serves as it's Interim CEO since June 25, 2024. Mr. Mack serves as Chief Financial Officer of Imcyse SA sinc...

리더십 팀

이름	위치	테뉴어	보상	소유권
Khalid Islam	Executive Chairman	7.8yrs	US$99.90k	3.65% $ 1.5m
Gene Mack	CFO & Interim CEO	less than a year	데이터 없음	0.056% $ 23.3k
Joanne Taylor	Senior Vice President of Research	2.4yrs	데이터 없음	데이터 없음
Terenzio Ignoni	Senior Vice President of Technical Operations	3.4yrs	데이터 없음	데이터 없음
Jonas Hannestad	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

경험이 풍부한 관리: GANX 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Khalid Islam	Executive Chairman	7.8yrs	US$99.90k	3.65% $ 1.5m
Dov Goldstein	Independent Director	3.8yrs	US$86.90k	0% $ 0
Samuel Broder	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gwen A. Melincoff	Independent Director	3.8yrs	US$69.90k	0% $ 0
Hans Hasler	Independent Director	3.8yrs	US$83.40k	0% $ 0
Eric Richman	Director	4.3yrs	US$12.50k	1.19% $ 493.2k
Jeffrey Riley	Independent Director	5.5yrs	US$85.40k	0.12% $ 48.6k
Claude Nicaise	Independent Director	3.8yrs	US$74.90k	0% $ 0

3.8yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: GANX 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Gain Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Gain Therapeutics, Inc. Announces CEO Changes

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Recent updates

Gain Therapeutics, Inc. Announces Presentation of Preclinical Data for the Product Candidate, GT-02287

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics, Inc. Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics, Inc. Announces CEO Changes

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.999898 million.

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Consensus EPS estimates upgraded to US$0.97 loss, revenue downgraded

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Consensus revenue estimates fall by 40%

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

New major risk - Financial position

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Consensus revenue estimates decrease by 11%, EPS upgraded

Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has filed a Follow-on Equity Offering.

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.62 loss per share (vs US$0.43 loss in 2Q 2022)

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Gain Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

High number of new and inexperienced directors

Gain Therapeutics, Inc. Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

Gain Therapeutics Announces Chief Executive Officer Changes

Gain Therapeutics appoints CEO

Gain Therapeutics, Inc. Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

Price target decreased to US$19.25

Consensus forecasts updated

Consensus forecasts updated

Gain Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$22.00

High number of new and inexperienced directors

Price target decreased to US$22.00

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid

Gain Therapeutics Presents Preclinical Data on Its Structurally Targeted Allosteric Regulators in Gba1 Gaucher Disease At the Worldsymposium 2022

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-Derived Ipsc Study Evaluating Star Compounds as A Treatment for Gaucher and Parkinson’S Disease

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Gain Therapeutics EPS misses by $0.29

Gain Therapeutics, Inc. Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related a-synucleopathies at the XXVI IAPRD World Congress

Gain Therapeutics, Inc. has completed an IPO in the amount of $40.000004 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령